Changsha, China, July 22, 2024 - Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited to announce the launch of its latest product, Y-Shape PEG NHS. This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers ...Learn More

Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to ...Learn More

Hunan Huateng Pharmaceutical Co., Ltd, a global leader in PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services, cordially invites you to visit our booth at CPhI Japan 2024, held from April 17th to 19th at Tokyo Big Sight, Tokyo, Japan. Event ...Learn More

Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, ...Learn More

Huateng Pharma, a Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates, is proud to announce its featured product line catering specifically to the veterinary industry. With a commitment to delivering high-quality solutions, Huateng ...Learn More